Posted by Michael Wonder on 18 Apr 2024
AskBio receives FDA fast track designation for AB-1002 investigational gene therapy program in congestive heart failure
18 April 2024 - AB-1002 is being studied for the treatment of adults with non-ischaemic cardiomyopathy and New York Heart Association class III heart failure symptoms.
Bayer AG and Asklepios BioPharmaceutical today announced that the US FDA has granted fast track designation for the AB-1002 program.
